5.30 +0.03 (0.57%)
After hours: 6:34PM EST
|Bid||5.27 x 800|
|Ask||5.30 x 800|
|Day's Range||5.20 - 5.45|
|52 Week Range||3.33 - 30.35|
|Beta (3Y Monthly)||1.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 5, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.50|
PHILADELPHIA, Dec. 11, 2018 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into an amendment of its credit agreement effecting the term A loans thereunder (Term A Loans) to provide the company greater flexibility with regard to its financial leverage ratio covenant applicable to such Term A Loans. With the amended leverage ratios, the company expects to be well within its financial covenants through the maturity date of the Term A Loans.
PHILADELPHIA , Dec. 5, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the BMO Capital Markets 2018 Prescription for Success Healthcare Conference ...
CORAL GABLES, FL / ACCESSWIRE / November 19, 2018 / Healthcare stocks have rallied during the last 3 trading sessions. On Friday, the market powered higher, lead by healthcare stocks. Furthermore, the idea that a split congress could be a good thing for healthcare stocks is offering a brighter outlook for some investors to look closer at several smaller healthcare companies that could be set to rebound.
Lannett's $50M distribution deal with Amneal will make Amneal the sole customer for Lannett's levothyroxine sodium tablets.
CORAL GABLES, FL / ACCESSWIRE / November 12, 2018 / New trends in Healthcare have helped push biotechnology stocks and healthcare stocks higher this year. Connected health is a new model for healthcare delivery, which provides healthcare services remotely. According to reports* the global connected healthcare market is expected to reach $105,337.5 Million by 2022 at a CAGR of 30.27% during the forecast period.
Lannett Co. Inc. shares soared more than 14% in premarket trade Monday, after the company unveiled an agreement with Amneal Pharmaceuticals Inc. for its Levothyroxine Sodium tablets, a treatment for an under-active thyroid. Lannett will receive a $50 million upfront payment. Lannett has previously announced that its distribution agreement with Jerome Stevens Pharmaceuticals, which included Levothyroxine Sodium tablets, expires on March 23, 2019 and will not be renewed. Amneal will be its sole customers for the tablets and will re-sell them to its customers. "For Lannett, this transaction guarantees $50 million of gross profit, which exceeded our previous projections for the 16 week period," Chief Executive Tim Crew said in a statement. The company will continue to distribute the other products in the Jerome Stevens agreement, namely Butalbital, Aspirin, Caffeine with Codeine Phosphate Capsules and Digoxin Tablets, through March 23. Shares have fallen 76.9% in 2018, while the S&P 500 has gained 4%.
PHILADELPHIA, Nov. 12, 2018 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into an agreement with Amneal Pharmaceuticals, Inc. (Amneal) with regard to Levothyroxine Sodium Tablets USP. Under the agreement, Amneal will be Lannett's sole customer for Levothyroxine Sodium beginning December 1, 2018 through March 23, 2019, and will re-sell the products to its customers. Lannett will receive an upfront payment of $50 million, other terms of the transaction were not disclosed. As previously announced, Lannett's distribution agreement with Jerome Stevens Pharmaceuticals (JSP), which includes Levothyroxine Sodium Tablets USP, expires on March 23, 2019 and will not be renewed.
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Lannett Company (LCI) have filed a shareholder complaint against the company's officers and directors for breaches of fiduciary duty from 2013 to the present for their role in allegedly causing Lannett to engage in a price-fixing scheme to attain its revenue goals and artificially inflate its common stock. Lannett develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States.
Lannett (LCI) delivered earnings and revenue surprises of 10.00% and 5.86%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Fiscal 2019 First Quarter Net Sales and Adjusted Net Income Ahead of Expectations - 16 Products Launched January to November 2018 that are Forecasted to Contribute Approximately $75 Million of Revenues ...
--Company Has Commenced Launch of Clarithromycin and Expects to Begin Marketing Entacapone In Early Calendar Year 2019-- PHILADELPHIA , Nov. 6, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today ...
NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
PHILADELPHIA, Nov. 1, 2018 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into an agreement with Rivopharm SA to be the exclusive U.S. distributor of Vardenafil Hydrochloride Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg, which is the AB-rated generic equivalent to Levitra® of Bayer Healthcare Pharmaceuticals Inc. Vardenafil Hydrochloride Tablets are indicated for the treatment of erectile dysfunction. Vardenafil Hydrochloride Tablets has an estimated IMS market value of approximately $94 million, although actual generic market values are expected to be lower.
PHILADELPHIA , Nov. 1, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 first quarter on Wednesday, November 7, 2018 , ...
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 26, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
NEW YORK, NY / ACCESSWIRE / October 26, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Lannett Company, Inc. ("Lannett" or the "Company") (LCI) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Lannett securities between February 7, 2018 and August 17, 2018, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
RADNOR, PA / ACCESSWIRE / October 25, 2018 / Kaskela Law LLC has filed an investor class action lawsuit against Lannett Company, Inc. (NYSE: LCI) ("Lannett" or the "Company") on behalf ...
NEW YORK, Oct. 25, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK , Oct. 24, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Lannett Company, Inc. (NYSE: LCI) from February 7, 2018 through August ...
NEW YORK, Oct. 24, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..